Influence of hydroxyethyl starch combined with strengthening anti-platelet therapy on the short-term clinical efficacy, TCD index and recurrence rate of patients with TIA secondary to cerebral artery stenosis / 中国基层医药

ABSTRACT

Objective To investigate the influence of hydroxyethyl starch combined with strengthening anti -platelet therapy on the short-term clinical efficacy,TCD index and recurrence rate of patients with TIA secondary to cerebral artery stenosis.Methods 80 patients with TIA secondary to cerebral artery stenosis were chosen,and they were randomly divided into two groups according to the digital table,each group in 40 cases.The control group received strengthening anti-platelet therapy alone,and the observation grouP received hydroxyethyl starch on the basis of control group.The short-term clinical efficacy,the blood flowvelocity of ACA and MCA before and after treatment,the TIA recurrence rate,the incidence of cerebral infarction and adverse reactions of both two groups were compared.Results The short-term effective rates of the control group and observation group were 77.50％,97.50％,respectively.The short-term effective rate of the observation group was significantly higher than that of the control group(x2 =12.33,P ＜ 0.05).The blood flow velocity of ACA and MCA of the control group after treatment were (51.05 ± 9.83) cm/s,(54.88 ± 6.62) cm/s,respectively,which were significantly lower than those of the observation group [(59.12 ± 12.07) cm/s,(62.65 ± 8.09) cm/s,t =3.17,2.96,4.03,4.74,3.67,4.05,all P ＜ 0.05].The TIA recurrence rate and the incidence rate of cerebral infarction of the control group were 22.50％,12.50％,respectively,which were significantly higher than those of the observation group(5.00％,0.00％,x2 =11.75,14.06,all P ＜ 0.05).The incidence rates of adverse reactions of the control group and observation group were 12.50％,10.00％,respectively.There was no significant difference in the incidence rate of adverse reactions between the two groups (x2 =1.75,P ＜ 0.05).Conclusion Hydroxyethyl starch combined with strengthening anti-platelet therapy in the treatment of patients with TIA secondary to cerebral artery stenosis can efficiently relieve the symptoms of neurological function,higher the level of cerebral blood perfusion,reduce the risk of TIA recurrence and cerebral infarction,and not increase the incidence of adverse reactions.